J Breast Cancer.
2020 Dec;23(6):672-673. 10.4048/jbc.2020.23.e62.
Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
- Affiliations
-
- 1Department of Oncology, Institut de Cancérologie Strasbourg, Strasbourg, France
- KMID: 2511854
- DOI: http://doi.org/10.4048/jbc.2020.23.e62
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Trastuzumab Exposure during Pregnancy with Invasive Breast Cancer
- Human Epidermal Growth Factor Receptor 2-positive Mucinous Carcinoma with Signet Ring Cell Differentiation, Which Showed Complete Response after Neoadjuvant Chemotherapy
- Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after BreastConserving Surgery
- Psoriasis Induced by Trastuzumab (Herceptin(R))
- Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
